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ABSTRACT
Adenosine fine tuning neuromodulation is a very subtle change, similar to what
e.g., a pianist does, modulating a sound through insertion of another sound;
so, modifying the characteristics of the previous sound. This is what adenosine
does to modulate neurotransmitter actions. Adenosine neuromodulation is operated
through high affinity inhibitory A1 and excitatory A2A receptors. These receptors
have the particularity of interacting with receptors for other neurotransmitters and
neuromodulators as well as with adenosine transport systems. This modulation is
involved in neuroprotection namely via adenosine A1 receptors in neurotoxicity
during hypoxia, reactive oxygen species insults either inhibiting NMDA receptors
or as part of interleukin-6 neuroprotecive effects. On the other hand A2A receptors
mainly trigger the action of several promoters of neuroprotection, e.g., BDNF and
GDNF.
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RESUMEN
Neuromodulación fina por adenosina y neuroprotección
La neuromodulación fina por adenosina supone un cambio muy sutil, similar
al que, por ejemplo, realiza un pianista, modulando un sonido a través de la inser-
ción de otro, modificando así las características del sonido previo. Esto es lo que
hace la adenosina para modular las acciones de los neurotransmisores. La neuro-
modulación por adenosina se realiza a través de receptores de alta afinidad inhi-
bitorios A1 y excitatorios A2. Estos receptores poseen la particularidad de interac-
cionar con receptores para otros neurotransmisores y neuromodulares, así como
con los sistemas de transporte de adenosina. Esta modulación está implicada en la
neuroprotección vía receptores de adenosina A1 en la neurotoxicidad producida
durante la hipoxia, daños producidos por las especies reactivas del oxígeno inhi-
biendo los receptores NMDA o como parte de los efectos neuroprotectores de la
interleukina-6. Por otro lado, los receptores A2A principalmente desencadenan la
acción de varios promotores de la neuroprotección, como el BDNF y el GDNF.
Palabras clave: Receptores de adenosina.—Neuromodulación.—Neuropro-
tección.
INTRODUCTION
At chemical synapses, neuromodulators exert a «fine tuning»,
a very subtle change, similar to what, for example, a pianist does,
modulating a sound (the effect of a neurotransmitter) through
insertion of another sound (the effect of a neuromodulator), so,
modifying the caracteristics of the previous sound. So far adenosine
fills completely the criteria of a neuromodulator (see 26).
In this paper I shall discuss the potential of this neuromodulator
as a neuroprotector, which also means, till certain point, to be
involved in neuroregeneration and brain repair.
Knowing how neuroregeneration occurs it is possible to conceive
processes of protecting the nervous system, in other words to induce
and to develop neuroprotection. The cellular elements and
the chemical neuromediators involved in brain insults act via
interconnections between the cellular elements and their secretions;
the immune system and the nervous system are highly regulated
in normal physiology, which benefits the organism. When neuronal
cells suffer insults the connections in the brain are deprived of
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the local control over microcirculation and necessary oxygen,
rendering membrane potentials useless to modulate neuronal
function. The fact that chemical mediators are already part
of normal physiology, whether during development or adulthood,
means that their activity can be modified by specific agonists and
antagonists to restore homeostasis or to promote the safe pathways
that can lead to regeneration. During the past decades considerable
experimental and clinical data have been accumulated regarding
cellular and biochemical events associated with neuroprotection,
neuroregeneration and brain repair.
Three situations related to neuroprotection will be discussed in
the context of adenosine-related medicines as therapeutical potential
agents. The points I shall emphasize are: first, the insults of neurons
caused by hypoxia/ischemia, which is a typical situation that occurs
during stroke; secondly, I will discuss the reactive oxygen species
(ROS) as a way to induce lesions in neurons and its relation to
neurodegenerative diseases and thirdly, how to enhance the putatitve
neuroprotective actions contained in neurotrophic factors, such as
e.g. the brain derived neurotrophic factor (BDNF) and the glial
derived neurotrophic factor (GDNF).
Before I go into these aspects I would like to give you briefly
some biographical notes about my research context that can explain
why a medical doctor graduated in 1965, who wishes to be a
psychiatrist enters into basic neuroscience research. In fact, when in
1957 I started my studies on Philosophy and in particular Psychology,
I was fascinated by Perception and in particular Behaviour. Why
that strange behaviour of the main character, Meursault of the Albert
Camus novel «L’Etranger»? I decided to go into the medical school
to become a Psychiatrist. It was indeed with great joy that in 1977
when the first edition of the book From Neuron to Brain by Stephen
Kuffler and John Nichols appear, I read in the preface: «We work
mostly on the machinary that enables neurons to function. Students
who become interested in the nervous system almost always tell us that
their curiosity stems from a desire to understand perception,
consciousness, behaviour, or other higher functions of the brain.
Knowing of our preoccupation with the workings of isolated nerve cells
or simple cell systems, they are frequently surprised that we ourselves
started with similar motivations, and they are even more surprised that
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we have retained those interests. In fact, we believe we are working
toward that goal (and in that respect probably we do not differ from
most of our colleagues and predecessors). We hope, to show that we
are pointed in the right direction».
However, when in 1964 I did the disciplines of psychiatry and
neurology, I have an enormous deception, there was almost no
help for psychiatric patients. Psychiatric hospitals were filled with
«prisoners-like», more than patients. So, I decided to give up
psychiatry. After spending almost four compulsory years as a Medical
Doctor of the Portuguese Army, two of them in Mozambique, I
started in 1970 my first studies on Neuropharmacology. The
scientific question was: how brain interferes with autonomic
responses? The idea was to relate the cardiotonic effects of ouabain
on the brain, with its cardiovascular actions, in particular blood
pressure (BP) and heart rate (HR). As HR is under the influence of
acetylcholine (ACh) we also measured by bioassay ACh release (27).
This sort of experimental approach had many limitations
resulting from being an in vivo investigation with many variables
involved and also because it was not possible to measure chemically
very tiny amounts of ACh. It was like being almost 2000 years back
in the History of Pharmacology. Being in the Real Academia Nacional
de Farmacia, I think it is appropriate to recall Galen (130-200 ac),
and his fluid theory of cerebral ventricles and nerves as vessels to
circulate fluids.
After two years of research under supervison of Fernando Peres-
Gomes, he decided to send me to Edinburgh to learn about the most
simple cholinergic synapse —the Neuromuscular Junction— as well
as to learn about measuring electrophysiologically ACh. Knowing
about this junction (synapse) one could start to know about central
nervous system synapses and in consequence to know about brain
functions and dysfunctions. This makes me fill closer to my initial
interest —psychiatry—. Also my readings of Egas Moniz (Nobel
Prize, 1949), who based upon Ramon y Cajal (Nobel Prize, 1906)
observations, wrote in 1953: «...Os neurónios encadeam-se e as
fibrilhas dos cilindraxis não se ligam em soldadura a outras células;
formam contactos através dos botões de Held, de forma variada [...]
Sobre esta noção anatómica, que devemos a Ramón y Cajal, concluí
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que essas sinapses, repetidas em míriadas de células, são a base
orgânica do pensamento. A vida psíquica normal depende do bom
funcionamento sináptico; e as perturbações mentais provêm do
desarranjo das sinapses», In «Como consegui realizar a
leucotomia prefrontal». Conferências Médicas Literárias VI,
strongly support my decision to go into basic research to study
synapses.
Two other important reasons that encouraged my interests on the
Neuromuscular Junction came from my readings of Claude Bernard,
(1813-1878), one of my scientific heroes. In 1849 he wrote the
important paper on «Action physiologique des venins (curare)»,
published at C. R. Sceances Soc. Biol. Ses Fil. 1: 90 where he states
that «Chez lez animaux le système nerveux et musculaire met tous ces
organes en sympathie ou en rapport les uns avec les autres», and in the
Physiology Course at the Univ. of Paris in the Sommaire de la «Vingt
et uniéme leçon, delivered on 28 mai 1856, he wrote: “le curare est
sans action sur les organes actifs de la circulation, et il n’enléve pas au
sang ses aptitudes physiologiques”. —Action du curare sur le systéme
nerveux: il abolit les manifestations du systéme nerveux et laisse
intact le systéme musculaire—. On peut prouver par lá que la
contractilité musculaire et l’excitabilité des nerfs moteurs sont deux
propriétés distinctes». The second important reason was the work
by the Nobel prize winners, Bernard Katz, Ulf Von Euler and Julius
Axelrod awarded jointly in 1970 for their discoveries concerning the
humoral transmitters in the nerve terminals and the mechanism
for their storage, release and inactivation. It happens that one of the
scientific «dilet» sons of Bernard Katz was Bernard Ginsborg just
moving in early seventies to the University of Edinburgh, where he
was going to be my supervisor.
ADENOSINE AND THE NEUROMUSCULAR JUNCTION
In the late sixties Bernard Katz and Paul Fatt taught Bernard
Ginsborg the secrets of Neuromuscular Transmission at the Univ
Coll, Lond. When Bernard Ginsborg moved to Edinburgh he started
to study the physiology and pharmacology of the Neuromuscular
Junction, and together with his post-doc, David Hirst. They were the
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first to describe that adenosine inhibits neurotransmitter release and
this was done using as a synapse the Rat Neuromuscular Junction
(12, 13). When I arrived in Edinburgh, Bernard Ginsborg asked me
to continue this work in another model —the Frog Neuromuscular
Junction— (32, 33), since in this model there is no margin of safety,
making this nicotinic cholinergic synapse more similar to the central
excitatory synapses, now known to be the glutamatergic synapses.
ADENOSINE AND THE CENTRAL NERVOUS
SYSTEM SYNAPSES
As described for its action on endplate potentials (EPPs),
adenosine at the frog neuromuscular junction, inhibited the
amplitude of the excitatory post-synaptic potentials (EPSPs) recorded
from the Guinea pig Olfactory cortex slices, as first described by
Okada & Kuroda (22). This work has been followed by the work of
Dunwiddie’s group, Stone’s group using rat hippocampal slices, as
well as by my group, in several publications since 1985 (see list in
PubMed), where it was described that the A1-receptor inhibitory
effects of adenosine and adenosine analogues on glutamatergic
transmission, possess almost all characteristics of those previously
observed using the frog neuromuscular junction as a model of
synaptic transmission.
Endogenous Adenosine
Adenosine antagonism, adenosine uptake inhibition, adenosine
deaminase, 5’-ecto-nucleotidase inhibition were used to manipulate
and to recognize the role of endogenous adenosine (29). In parallel
we came across with the existence of A2A excitatory effects at the
neuromuscular junction (29) and in the hippocampus, the first
description was the effect of an A2A agonist (CGS21680) on rat
hippocampal glutamatergic synaptic transmission (35). This was
further supported by in situ hybridization autoradiograms, which
confirmed the co-expression of A1 and A2A in hippocampal brain
slices. The relative importance of A2A receptors vis à vis A1 receptors
in the hippocampus was shown in 1996 when A2A receptors prove to
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be more effective than A1 receptors in high frequency stimulation
(7), and in 2003 when it was demonstrated that A2A receptors are
more effective than A1 receptors in aged than in young rats (see 31).
It appears that whilst the most predominant action of extracellular
adenosine in the hippocampus is A1-receptor mediated inhibition of
synaptic transmission, the less abundant A2A-receptor are devoted to:
prime, trigger or modulate the action and/or inactivation of other
neuromodulators and, therefore, to fine-tune neuronal activity (37).
Other interesting observations on A2A effects include stimulation by
A2A-receptors of the carotid body arterial chemoreceptors and
ventilation. Since hypoxia is the physiological stimuli of carotid body
chemoreceptors, the finding that a substance, preferentially released
by hypoxia-adenosine, stimulates ventilation seems to close a circle
of understanding the mechanisms involved in hypoxic stimulation of
ventilation (20, 21).
ADENOSINE AND NEUROPROTECTION
What means neuroprotection?
It is a collective therapeutic approach to provide neuronal
survival. In a normal neuron the amount of O2 supplied is according
to the cell needs, ATP production fills the needs of the cell to make
the pumps to work and pH is established around 7.0. When hypoxia
occurs there is necrosis in some cells and in the penumbra involving
necrosis, the cells enter into a process of apoptosis where it will be
possible to rescue some of the cells that did not enter into the
necrosis processes.
How could we protect nerve cells from insults?
By this I mean to protect neurons from ischemia and/or hypoxia,
from trauma, from neurodegenerative diseases. What do all these
situations have in common? The answer is the death of neurons. So
the emergent question is how neurons are killed? Glutamate is now
accepted to be the main «killer» of neurons after brain insults.
Glutamate acts both as a primary excitatory neurotransmitter and a
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potential neurotoxin within the mammalian brain. Experimental
evidence suggests that hyperactivity of the glutamate NMDA-receptor
mediated current system contributes to neuronal death. Also, this
neural injury is followed by gliosis which has been linked to the
severity of brain lesions. In this context, investigation of substances
that can selectively inhibit the glutamate NMDA receptor subtype in
humans, while also therapeutically controlling glial cell responses and/
or triggering the release of neuroprotective factors from these cells
following brain insults, would be of great help in neuroprotection.
This has led to the application of pharmacological strategies to limit
the lesions and subsequent neurological deficits. The research on
pharmacological agents will help to promote functional rewiring of
brain after injury in order to obtain neural repair and neurological
rehabilitation.
So, the immediate question is: what occurs at a glutamatergic
synapse during insults? The actual consensus is that too much
glutamate is being released and the NMDA-R «till then silent» is
opened and becomes too much permeable to Ca2+ ions. Because the
cell suffers from energy supply i.e. there is no ATP available for the
Ca2+ pumps to expel the excess of Ca2+, the neurons die. According
to this theory if one inhibits glutamate release during insults and/or
inhibits NMDA-R activation one could save neurons from the
deleterious effects of glutamate.
How one could inhibit glutamate release during insults?
It is well known that if one measures synaptic transmission
activity (e.g EPSPs) from rat hippocampal slices, and hypoxia is
applied for 90 minutes, this insult inhibits and eventually completely
blocks synaptic transmission, an effect that is completely recovered
when hypoxia is terminated. It is well established that the inhibitory
neurotransmitter, gamma-amino-butyric acid (GABA), inhibits
glutamatergic transmission in normoxic conditions but it does not
work during hypoxia (see 19).
If GABA, the main inhibitory transmitter in the brain, is not
apparently effective during hypoxia to control glutamate involvement
in the hypoxia insult, the question one could ask is: which other
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substances, also abundant in the brain, as GABA, will have the ability
to inhibit glutamatergic transmission?
In the brain, besides the classical neurotransmitters, there are
substances that behave as neuromodulators of neurotransmitters and
even of neuromodulators themselves see e.g. (35). These substances,
in contrast with classical neurotransmitters, are not contained in
vesicles, are not released through exocytosis but through transporters,
and can be released post-synaptically to act both pre- and post-
synaptically on specific receptors. One of these substances intensively
studied in the last 25 years is adenosine.
Adenosine exists in all cells, and is released from apparently all
insulted cells, including neurons and glial cells. Once in the
extracellular space, adenosine modifies cell functioning by operating
G protein-coupled receptors.
Adenosine as a neuromodulator
Adenosine is indeed consensually recognised as a very important
substance in the homeostasis of the cells of the nervous system, being
in relation to cardio-protection once named «a signal of life» (11). It
modulates the activity of the nervous system by acting pre-synaptically
(by inhibiting or facilitating transmitter release), post-synaptically,
and/or non-synaptically. The way adenosine is doing this is through
activation of physiologically relevant high affinity adenosine receptors
(A1, A2A) as well as of a lower affinity receptors (A2B, A3), which might
be relevant in pathological conditions (see 31). Besides affecting
directly the neuronal cells, adenosine receptor activation also
influences the action of other neurotransmitters as well as of other
neuromediators. Because adenosine uses very subtle manners to
participate in these interactions, it acts as a fine tuner, considering
that in this way, adenosine is involved in a very sophisticated interplay
between its own receptors and the receptors for other synaptic
mediators. From these modulatory actions it is possible to anticipate
potential therapeutic applications, especially when these actions are
mediated by high-affinity adenosine A2A receptors in regions where
clear functions have been identified. The A2A receptor is highly
expressed in the striatopallidal GABAergic neurones and expressed in
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lower levels in other brain regions. A2B possess low levels of expression
in the brain. A3 has apparently intermediate levels of expression in
the human cerebellum and hippocampus and low levels in most of
the brain (31). The well known striatal A2A/D2 receptor interactions
may offer new therapeutic leads for basal ganglia disorders, such
as Parkinson’s disease and Huntington’s chorea, as well as for
schizophrenia (31). Inhibition of D2 receptors in the ventral striatum
seems to be associated with the antipsychotic effect of neuroleptics,
while inhibition of dopamine D2 receptors in the dorsal striatum
is related to their extrapyramidal side effects. In the periphery,
the interaction of A2A receptors with other receptors that regulate
acetylcholine release from motor nerve terminals could reveal the
importance of A2A receptors when deficits in acetylcholine release
occur (e.g. myasthenic syndromes). The excitatory effects of A2A
receptors on acetylcholine release might prove useful when developing
cognitive enhancers that by increasing acetylcholine release could be
of therapeutic interest in dementia (e.g. Alzheimer’s disease). Since
the adenosine A1 receptors inhibit neurotransmitter release, and
inhibit A2A receptor functioning, one can also predict that adenosine-
related medicines that combine adenosine A1 receptor blockade with
A2A receptor activation will be useful in situations where an increase
in neurotransmitter release is needed. There are also situations where
A2A receptor activation might prove to be excitotoxic (e.g. increase in
glutamate release) and, therefore, A2A antagonism will be needed (31).
It is worth noting that after several years of concentrating most
of the adenosine research efforts on adenosine A1 receptors, the
adenosine A2A prove to be a very promising receptor in terms of
understanding the subtle ways used by this nucleoside to implement
a harmonic and fine control of synaptic activity.
Although adenosine is not a neurotransmitter on its own, it shares
via A1 activation many properties attributed to the major inhibitory
neurotransmitter —GABA, i.e. decreases excitability mediated
by glutamate—. So GABA and adenosine constitute key molecules
in the control of glutamatergic synaptic transmission in the central
nervous system (see above). Adenosine is able to functionally
disconnect GABAergic interneurones by inhibiting their glutamatergic
input, a process that might be particularly relevant under conditions
of intense adenosine release, such as it happens during hypoxia. Thus,
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although indirectly, adenosine inhibitory (A1) receptors might control
GABAergic functioning. Direct excitation of GABAergic nerve
terminals by adenosine might occur through A2A receptors (31).
Adenosine as a modulator of other neuromediators
Besides its direct pre- and post-synaptic actions on neurons,
adenosine is rich in nuances of priming, triggering and braking the
action of several neurotransmitters and neuromodulators. Adenosine
is also able to «synchronize» or «desynchronise» receptor activation
for neuropeptides such as calcitonin gene-related peptide (CGRP)
and vasoactive intestinal peptide (VIP), nicotinic autofacilitatory
receptors, NMDA receptors, metabotropic glutamate receptors, as
well as adenosine own receptors (37). Also the inhibitory action of
adenosine A2A and A2B receptors on nitric oxide (NO) production and
iNOS expression in glial cells (6) can constitute a partnership aiming
neuronal protection after insults. Of particular importance is the
recent finding by Chao (6) that TrkB neurotrophin receptors can be
activated in the absence of neurotrophins, providing that A2A
receptors are activated. The authors emphasize that although there
are suggestions proposing the use of neurotrophins in Alzheimer’s
dementia, amyotrophic lateral sclerosis and peripheral sensory
neuropathy, it has been difficult to deal with delivery and
pharmacokinetics of these molecules. Thus, the possibility of
promoting trophic effects by manipulating the degree of activation
of A2A receptors, may prove highly relevant in neurodegenerative
disorders where sustained actions on survival signalling pathways
are needed.
Selective activation of adenosine A2A instead of A1 receptors
Adenosine A1 and A2A receptors can co-exist in the same nerve
terminal (35). Evidence for this arrived from the observation that an
A1 receptor agonist acting pre-synaptically inhibits and an A2A
receptor agonist acting also presynaptically enhances the amplitude
of endplate potentials recorded intracellularly from a single endplate,
which in the case of the striated muscle receives input from only one
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nerve ending. The coexistence of both subtypes of high affinity
adenosine receptors prompted the question on how adenosine
chooses to activate A1 or A2A receptors, and under which conditions
does it discriminate between these receptors. It appears that instead
of the classical view that endogenous adenosine activates A1 receptors
regardless of whether it is released as such or formed from adenine
nucleotides, adenosine formed from adenine nucleotides acts
preferentially on A2A receptors, and adenosine released as such acts
preferentially on A1 receptors (9). This may result from different
localization of A1 and A2A receptors in relation to adenosine release
sites and ecto-5’-nucleotidase localization. An indication that burst-
like adenosine formation from released adenine nucleotides might
be, at least in part, responsible for its preferential action on A2A
receptors, is the finding that when motor nerve endings are
stimulated at low frequency, i.e., under conditions where smaller
amounts of adenine nucleotides are released, the ecto-5’-nucleotidase
inhibitor, a,b-methylene ADP (AOPCP), enhances (31) rather than
inhibits acetylcholine release. Indeed, the pattern of neuronal firing
influences the pattern of purine release and extracellular formation,
and in consequence, influences the way purines modulate synaptic
transmission. High frequency stimulation favours ATP release, and
adenosine formation, which preferentially activates adenosine A2A
receptors activation, whereas low frequency stimulation favours
adenosine release, and preferential adenosine A1 receptor activation
(see 31).
Modulation of NMDA receptors
In the isolated rat hippocampal neurons, A1 receptor activation
inhibits NMDA receptor-mediated currents (34). In the hippocampus
A1 receptors are also inhibitory of glutamate release and A2A-receptors
facilitate glutamatergic synaptic transmission (31). Interestingly, the
inhibitory action of A1 receptor agonists on NMDA receptor mediated
currents in hippocampal neurons is observed in a concentration
range compatible with a tonic inhibitory action of adenosine. Due to
the important role played by NMDA receptors in synaptic plasticity
phenomena, as well as in neuronal injury after prolonged
stimulation/depolarisation conditions, it is conceivable that the
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ability of A1 receptors to inhibit NMDA currents is the basis of the
A1 receptor mediated inhibition of synaptic plasticity (LTP and LTD)
as well as contributes to A1 receptor mediated neuroprotective
actions (31).
To summarize this point I would like to stress that adenosine
exerts pre-, post- and non-synaptic effects by acting on high affinity
receptors: A1 and A2A. There are also low affinity receptors: A2B
and A3, but so far their activation is not apparently related with
neuromodulation with potential implications for neuroprotection.
Adenosine-Receptor interactions with Adenosine transporter
NECA activates adenosine tranport in cultured chromaffin cells
(8). This was the first work to making connection between adenosine
receptors and adenosine transport. Recently (24), using hippocampal
synaptosomes described the nature of this receptor, an A2A receptor,
which when activated enhances adenosine uptake, and that A2A
receptor activation enhances adenosine release. So, it appears that
A2A receptors regulate adenosine transporters influencing the
extracellular availability of this nucleoside.
HYPOXIA RELEASES ADENOSINE
It is well established and consistent that after hypoxia/ischemia
insults there is release of adenosine into the synaptic cleft. This
adenosine is responsible for the inhibition of synaptic transmission
during hypoxia, since the A1-receptor antagonist, a xanthine
derivative, DPCPX, attenuates this inhibitory effect of hypoxia by
at least 50%. Therefore, the inhibitory effect of hypoxia is a
consequence of A1-receptor activation by huge amounts of adenosine
being released (34). One interesting aspect in the adenosine effect
is that if one tries to recover from hypoxia in the presence of the A1
antagonist, DPCPX, the recovery is never complete as it happens
during recovery without A1 blockade. This suggests that adenosine is
absolutely needed for complete recovery from hypoxia. This effect of
adenosine is a consequence of pre-synaptic inhibition of glutamate
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release and subsequent reduction of NMDA-receptor activation (34).
So, adenosine A1-receptor activation by released adenosine depresses
hippocampal synaptic transmission during hypoxia but is a process
that facilitates recovery upon re-oxygenation.
CEREBRAL ISCHEMIA AND TRAUMA
Cerebral ischemia leads to brain damage caused by pathogenetic
mechanisms that are also activated by neurotrauma. These
mechanisms include among others excitotoxicity, overproduction of
free radicals, inflammation and apoptosis. Furthermore, cerebral
ischemia and trauma both trigger similar auto-protective mechanisms
including the production of heat shock proteins, anti-inflammatory
cytokines and endogenous antioxidants. Neuroprotective therapy aims
at minimizing the activation of toxic pathways and at enhancing the
activity of endogenous neuroprotective mechanisms. According to
(18), the similarities in the damage-producing changes in endogenous
substances in the brain may imply that neuroprotective compounds
found to be active against one of these conditions may indeed be also
protective in the other.
Hypothermia
The use of hypothermia to treat various neurological emergencies,
initially introduced into clinical practice in the 1940s and 1950s, had
been considered without interest by the 1980s. However, in the early
1990s, there was a revival of its use in the treatment of severe
traumatic brain injury. The success of mild hypothermia led to the
broadening of its application to many other neurological emergencies.
Mild hypothermia has been applied with varying degrees of success in
many neurological emergencies, including traumatic brain injury,
spinal cord injury, ischemic stroke, subarachnoid haemorrhage out-
of-hospital cardiopulmonary arrest, hepatic encephalopathy, perinatal
asphyxia (hypoxic-anoxic encephalopathy), and infantile viral
encephalopathy. According to (15), there is no total consensus on the
efficacy and safety of mild hypothermia though preliminary clinical
studies have shown that mild hypothermia can be a feasible and
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relatively safe treatment. Recently it has been shown in vitro patch
clamp studies that in conditions of 32 ºC, adenosine inhibits NMDA
receptor currents in hypoxia suggesting that adenosine might exert
neuroprotection during hypothermia (34).
In summary, during hypoxia the neuroprotection induced by
adenosine operates both a decrease of neurotransmitter release
via inhibition of pre-synaptic calcium entry by blocking calcium
channels (28) and post-synaptically inhibiting calcium entry via
inhibition of NMDA-receptors.
Finally I also would like to mention our recent observations on
stimulation with interleukin-6 (IL-6), which increases A1 receptor-
mediated inhibition of synaptic transmission. In WT but not in IL6-
KO mice, seizures induce adenosine A1 receptor expression. These
observations reinforce the role of adenosine as an anti-epileptic
agent. IL-6-induced amplification of A1 receptor function enhances
the responses to readily released adenosine during hypoxia, enables
neuronal rescue from glutamate-induced death, and protects animals
from chemically induced convulsing seizures. Taken together, these
results suggest that IL-6 minimizes the consequences of excitotoxic
episodes on brain function through the enhancement of endogenous
adenosinergic signaling (see 2).
REACTIVE OXYGEN SPECIES (ROS)
During brain insults with xanthine-xanthine oxidase there is
production of reactive oxygen species (ROS). It was described by
Almeida et al (1) that the synaptic inhibition induced by ROS needs
adenosine to completely recover in contrast with what happens in
the presence of adenosine A1 receptor blockade with DPCPX (1).
ENHANCEMENT OF NEUROPROTECTIVE EFFECTS OF
NEUROTROPHIC FACTORS
Neurotrophic factors have been shown to have potential
therapeutic applications in neurodegenerative diseases, and nerve
growth factor (NGF) is neuroprotective in models of excitotoxicity.
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NGF administration, in the acute, post-traumatic period following
fluid-percussion brain injury, apparently improves post-traumatic
cognitive deficits (39) and a neurotrophic factor treatment following
traumatic brain injury is neuroprotective (16). Brain-derived
neurotrophic factor (BDNF) has been shown to be neuroprotective
in models of excitotoxicity, axotomy and cerebral ischemia. Blaha
et al. (3) demonstrated the therapeutic potential of brain-derived
neurotrophic factor following traumatic brain injury in the rat.
Neurotrophic factors are involved in neuronal maturation during
development, and protect neurons in experimental models of
neurodegenerative diseases. However, because of the blood brain
barrier it is very difficult to deliver these factors into the brain. A way
to overcome this difficulty was implemented by (38) using trial
infusions of nerve growth factor (NGF) in three patients with
Alzheimer’s disease. NGF was infused continuously through a
neurosurgically implanted cannula into the lateral ventricles of
the brain (38). However, technical difficulties discouraged the
continuation of this therapy.
BDNF is a neurotrophin abundant in the brain and recently it
has been shown that BDNF applied acutely facilitates synaptic
transmission if, before its application one depolarises the preparation
with potassium (4). Also in hippocampal synaptosomes BDNF
facilitates potassium-evoked glutamate release providing
synaptosomes have been previously depolarised by potassium (5).
Another group (17) showed that A2A receptors induce
phosphorylation of BDNF-TrkB-receptors. Since depolarisation
enhances the release of adenosine our group (see 9) decided to
investigate if activating A2A receptors we could selectively facilitate
BDNF actions on synaptic transmission. In fact with the activation
of A2A receptors with selective agonists or by increasing the adenosine
production in the brain with adenosine kinase inhibitors (e.g.
iodotubercidin), it is possible to induce facilitatory effects of BDNF
on synaptic transmission in hippocampal slices (see Figure 1). In
non-A2A pre-conditioned slices there is no BDNF effect on synaptic
transmission (9). It therefore appears to exist potential for the use of
A2A agonists or substances such as adenosine kinase inhibitors, which
through peripheral administration could wake up «sleeping»
neurotrophic factors in order to induce neuroprotection. This is also
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true in ageing (10) where neuroprotection is hardly needed. There is
a relationship between age-related changes in the density of TrkB
receptors and adenosine A2A receptors on what concerns BDNF-
induced enhancement of synaptic transmission in the hippocampus
(10). This should be taken into consideration whenever evaluating
BDNF actions in nerve cells, and may prove relevant in the design
of BDNF-based therapeutic strategies.
FIGURE 1. Mechanisms involved in the activation adenosine A2A-receptors.
It is proposed an intracellular cascade involving the cyclic AMP/PKA and its
potential relationship with the BDNF enhancement of synaptic transmission.
Also GDNF (14) in striatum promotes release of dopamine. GDNF
has been pointed out as a potential therapeutic approach in the
management of Parkinson’s disease (25). So, the prevention of GDNF
effect by A2A receptor antagonism point towards the need of further
studies on the consequences of long-term therapy with A2A receptor
blockers in neurodegenerative diseases where neurotrophic factors
may play a beneficial role. One issue that should be explored in the
future is the optimal time window for combined beneficial effects
for GDNF and A2A receptor agonists/antagonists. If, in the late stages
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of neurodegenerative diseases, A2A receptor antagonists can be
advantageous, in the early stages, where an enhancement of
neurotrophic factors should be highly desirable, A2A receptor
antagonists should be avoided in order to allow neurotrophic
influences.
Perspectives to explore the potential use of adenosine
to induce neuroprotection
By using A2A agonists or adenosine kinase inhibitors (which
induce the production of considerable amounts of endogenous
adenosine) that cross blood brain barrier, it would be possible to
promote the facilitation of BDNF or GDNF actions on synaptic
transmission (see Figure 2).
FIGURE 2. Perspectives to explore the potential use of adenosine to induce
neuroprotection. By using A2A agonists or adenosine kinase inhibitors
(which induce the production of considerable amounts of endogenous adenosine)
that cross blood brain barrier, it would be possible to promote the facilitation
of BDNF on synaptic transmission.
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CONCLUSIONS
1. Synaptic transmission during neuronal insults is under tight
control of endogenous extracellular adenosine.
2. A1-Receptor minimize the activation of toxic pathways e.g.
inhibiting glutamate release, inhibiting NMDA receptor-
mediated currents, and IL-6 facilitates A1-Receptor inhibition,
and A2A-Receptor interplays with receptors for other
neuromodulators via subtle modifications of fine tuning,
«synchronizing» or «desynchronizing» receptor activation.
3. A2A-Receptors enhance the activity of endogenous
neuroprotective mechanisms e.g. the action of neurotrophic
factors, which are devoted to protect neurons from lesions
(e.g. BDNF, GDNF), so, by A2A receptor activation one can
overcome difficulties found with the use of neurotrophins in
neurodegenerative disorders.
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